Results 71 to 80 of about 14,237 (205)

Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington’s disease mice [PDF]

, 2020
Transcriptional and epigenetic alterations occur early in Huntington's disease (HD), and treatment with epigenetic modulators is beneficial in several HD animal models.
Wu, Jie, Thompson, Leslie M, Stocksdale, Jennifer T, Reidling, Jack C, Adam, Miriam, Fraenkel, Ernest, Lim, Ryan G, Wassie, Brook T., Casale, Malcolm S, Kedaigle, Amanda J, Wassie, Brook   +10 more
core   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Biomaterials for modulating cellular responses of endogenous tendon stem/progenitor cells: A promising avenue for tendon regeneration

BMEMat, EarlyView.
This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu, Renwang Sheng, Mumin Cao, Ludvig J. Backman, Yucheng Gao, Hao Wang, Cheng Zhang, Jialin Chen, Wei Zhang, Yunfeng Rui   +9 more
wiley   +1 more source

iRGD Tumor-Penetrating Peptide-Modified Nano-Delivery System Based on a Marine Sulfated Polysaccharide for Enhanced Anti-Tumor Efficiency Against Breast Cancer

International Journal of Nanomedicine, 2022
Bowei Chen,1,* Xiaohong Liu,1,* Yunan Li,1 Tianhe Shan,1 Liya Bai,1 Chunyu Li,2 Yinsong Wang1 1School of Pharmacy, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), Tianjin ...
Chen B, Liu X, Li Y, Shan T, Bai L, Li C, Wang Y   +6 more
doaj  

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC

Journal of Experimental & Clinical Cancer Research, 2019
Background The bromodomain and extra-terminal domain (BET) inhibitor is a type of anti-tumor agent, currently being evaluated in phase I and II clinical trials for cancer therapy.
Yalei Yin, Mingju Sun, Xi Zhan, Changqing Wu, Pengyu Geng, Xiaoyan Sun, Yunsong Wu, Shuijun Zhang, Jianhua Qin, Zhengping Zhuang, Yang Liu   +10 more
doaj   +1 more source

Blocking the Bromodomains Function Contributes to Disturbances in Alga Chara vulgaris Spermatids Differentiation

Cells, 2020
Bromodomain containing (BRD) proteins play an essential role in many cellular processes. The aim of this study was to estimate activity of bromodomains during alga Chara vulgaris spermatids differentiation. The effect of a bromodomain inhibitor, JQ1 (100
Agnieszka Wojtczak
doaj   +1 more source

BRD9 inhibition as potential treatment option for testicular germ cell tumors

Andrology, EarlyView.
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen, Christine Sanders, Florian Fronhoffs, Kai Funke, Glen Kristiansen, Hubert Schorle   +5 more
wiley   +1 more source

NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy [PDF]

Molecular Cancer Therapeutics, 2015
Abstract Genetically engineered mouse models of lung cancer have demonstrated an important role in understanding the function of novel lung cancer oncogenes and tumor-suppressor genes identified in genomic studies of human lung cancer. Furthermore, these models are important platforms for preclinical therapeutic studies.
Chunxiao, Xu, Kevin A, Buczkowski, Yanxi, Zhang, Hajime, Asahina, Ellen M, Beauchamp, Hideki, Terai, Yvonne Y, Li, Matthew, Meyerson, Kwok-Kin, Wong, Peter S, Hammerman   +9 more
openaire   +2 more sources

Additional file 1 of The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma

, 2023
Additional file 1: Figure S1. Pharmaceutical drug screening and Depmap sgRNA screening indicated that epigenetic inhibitor JQ1 and cell cycle inhibition are more likely to be associated with joint lethality. A) Bar plot of the average and maximum synergy
Mei Feng (281903), Hao Xu (6530), Wenyuan Zhou (9733194), Yisheng Pan (15217730)   +3 more
core   +1 more source